209 related articles for article (PubMed ID: 15256978)
1. Austrian infliximab experience in Crohn's disease: a nationwide cooperative study with long-term follow-up.
Wenzl HH; Reinisch W; Jahnel J; Stockenhuber F; Tilg H; Kirchgatterer A; Petritsch W
Eur J Gastroenterol Hepatol; 2004 Aug; 16(8):767-73. PubMed ID: 15256978
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of repeated infliximab infusions for Crohn's disease: 1-year clinical experience.
Cohen RD
Inflamm Bowel Dis; 2001 May; 7 Suppl 1():S17-22. PubMed ID: 11380038
[TBL] [Abstract][Full Text] [Related]
3. Immunomodulators and "on demand" therapy with infliximab in Crohn's disease: clinical experience with 400 infusions.
Kinney T; Rawlins M; Kozarek R; France R; Patterson D
Am J Gastroenterol; 2003 Mar; 98(3):608-12. PubMed ID: 12650795
[TBL] [Abstract][Full Text] [Related]
4. Infliximab in treatment of Crohn's disease: the Milan experience.
Ardizzone S; Colombo E; Maconi G; Bollani S; Manzionna G; Petrone MC; Bianchi Porro G
Dig Liver Dis; 2002 Jun; 34(6):411-8. PubMed ID: 12132788
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness and tolerability of repeated treatment with infliximab in patients with Crohn's disease: a retrospective data analysis in Germany.
Witthöft T; Ludwig D
Int J Colorectal Dis; 2005 Jan; 20(1):18-23. PubMed ID: 15459773
[TBL] [Abstract][Full Text] [Related]
6. Infliximab for Crohn's disease: the first 500 patients followed up through 2009.
Seminerio JL; Loftus EV; Colombel JF; Thapa P; Sandborn WJ
Dig Dis Sci; 2013 Mar; 58(3):797-806. PubMed ID: 23053885
[TBL] [Abstract][Full Text] [Related]
7. Infliximab treatment for Crohn's disease: one-year experience in a Dutch academic hospital.
Hommes DW; van de Heisteeg BH; van der Spek M; Bartelsman JF; van Deventer SJ
Inflamm Bowel Dis; 2002 Mar; 8(2):81-6. PubMed ID: 11854604
[TBL] [Abstract][Full Text] [Related]
8. [Treatment of Crohn's disease with anti-TNF alpha antibodies (infliximab): results of a multicentric and retrospective study].
Doubremelle M; Bourreille A; Zerbib F; Heresbach D; Metman EH; Beau P; Gournay J; Galmiche JP
Gastroenterol Clin Biol; 2002 Nov; 26(11):973-9. PubMed ID: 12483127
[TBL] [Abstract][Full Text] [Related]
9. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease.
Borrelli O; Bascietto C; Viola F; Bueno de Mesquita M; Barbato M; Mancini V; Bosco S; Cucchiara S
Dig Liver Dis; 2004 May; 36(5):342-7. PubMed ID: 15191204
[TBL] [Abstract][Full Text] [Related]
10. Safety of infliximab in Crohn's disease: a large single-center experience.
Hamzaoglu H; Cooper J; Alsahli M; Falchuk KR; Peppercorn MA; Farrell RJ
Inflamm Bowel Dis; 2010 Dec; 16(12):2109-16. PubMed ID: 20848473
[TBL] [Abstract][Full Text] [Related]
11. Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease.
Kugathasan S; Werlin SL; Martinez A; Rivera MT; Heikenen JB; Binion DG
Am J Gastroenterol; 2000 Nov; 95(11):3189-94. PubMed ID: 11095340
[TBL] [Abstract][Full Text] [Related]
12. Infliximab dependency in pediatric Crohn's disease: long-term follow-up of an unselected cohort.
de Ridder L; Rings EH; Damen GM; Kneepkens CM; Schweizer JJ; Kokke FT; Benninga MA; Norbruis OF; Hoekstra JH; Gijsbers CF; Escher JC
Inflamm Bowel Dis; 2008 Mar; 14(3):353-8. PubMed ID: 18069674
[TBL] [Abstract][Full Text] [Related]
13. Response to infliximab is related to disease duration in paediatric Crohn's disease.
Lionetti P; Bronzini F; Salvestrini C; Bascietto C; Canani RB; Dé Angelis GL; Guariso G; Martelossi S; Papadatou B; Barabino A
Aliment Pharmacol Ther; 2003 Aug; 18(4):425-31. PubMed ID: 12940928
[TBL] [Abstract][Full Text] [Related]
14. Infliximab: an updated review of its use in Crohn's disease and rheumatoid arthritis.
Keating GM; Perry CM
BioDrugs; 2002; 16(2):111-48. PubMed ID: 11985485
[TBL] [Abstract][Full Text] [Related]
15. [Infliximab therapy in children and adolescents with refractory Crohn's disease in the Netherlands; experience with 23 patients].
de Ridder L; Escher JC; Taminiau JA
Ned Tijdschr Geneeskd; 2002 Oct; 146(40):1879-83. PubMed ID: 12395595
[TBL] [Abstract][Full Text] [Related]
16. Infliximab in Crohn's disease: first anniversary clinical experience.
Cohen RD; Tsang JF; Hanauer SB
Am J Gastroenterol; 2000 Dec; 95(12):3469-77. PubMed ID: 11151879
[TBL] [Abstract][Full Text] [Related]
17. Clinical experience with infliximab therapy in 100 patients with Crohn's disease.
Farrell RJ; Shah SA; Lodhavia PJ; Alsahli M; Falchuk KR; Michetti P; Peppercorn MA
Am J Gastroenterol; 2000 Dec; 95(12):3490-7. PubMed ID: 11151882
[TBL] [Abstract][Full Text] [Related]
18. Infliximab for Crohn's disease in clinical practice: the experience of a single center in romania.
Gheorghe L; Gheorghe C; Badea M; Vădan R; Pârvulescu I; Toader C; Tugui L; Papuc O; Ionescu R; Preda C; Călin I; Diculescu M
Rom J Gastroenterol; 2003 Mar; 12(1):7-13. PubMed ID: 12673373
[TBL] [Abstract][Full Text] [Related]
19. Infliximab dependency in a national cohort of children with Crohn's disease.
Wewer V; Riis L; Vind I; Husby S; Munkholm P; Paerregaard A
J Pediatr Gastroenterol Nutr; 2006 Jan; 42(1):40-5. PubMed ID: 16385252
[TBL] [Abstract][Full Text] [Related]
20. Methotrexate for induction of remission in refractory Crohn's disease.
McDonald JW; Tsoulis DJ; Macdonald JK; Feagan BG
Cochrane Database Syst Rev; 2012 Dec; 12():CD003459. PubMed ID: 23235598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
